HomeCompareBYRG vs JNJ

BYRG vs JNJ: Dividend Comparison 2026

BYRG yields 200000.00% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BYRG wins by $58669749657316.91M in total portfolio value
10 years
BYRG
BYRG
● Live price
200000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$58669749657316.95M
Annual income
$29,229,917,576,186,618,000.00
Full BYRG calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — BYRG vs JNJ

📍 BYRG pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBYRGJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BYRG + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BYRG pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BYRG
Annual income on $10K today (after 15% tax)
$17,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$24,845,429,939,758,625,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, BYRG beats the other by $24,845,429,939,758,620,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BYRG + JNJ for your $10,000?

BYRG: 50%JNJ: 50%
100% JNJ50/50100% BYRG
Portfolio after 10yr
$29334874828658.49M
Annual income
$14,614,958,788,093,310,000.00/yr
Blended yield
49.82%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

BYRG
No analyst data
Altman Z
251.3
Piotroski
4/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BYRG buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBYRGJNJ
Forward yield200000.00%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%28%
Portfolio after 10y$58669749657316.95M$30.3K
Annual income after 10y$29,229,917,576,186,618,000.00$4,689.40
Total dividends collected$56061863852165.77M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BYRG vs JNJ ($10,000, DRIP)

YearBYRG PortfolioBYRG Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$10,010,700$10,000,000.00$10,592$272.30+$10.00MBYRG
2$4,688,608,645$4,677,897,196.26$11,289$357.73+$4688.60MBYRG
3$1,028,819,904,372$1,023,803,093,122.04$12,123$472.89+$1028819.89MBYRG
4$106,078,775,252,965$104,977,937,955,286.78$13,141$629.86+$106078775.24MBYRG
5$5,171,441,148,292,717$5,057,936,858,772,045.00$14,408$846.81+$5171441148.28MBYRG
6$120,757,381,614,481,280$115,223,939,585,808,080.00$16,021$1,151.60+$120757381614.47MBYRG
7$1,386,487,620,315,818,000$1,257,277,221,988,323,000.00$18,122$1,588.22+$1386487620315.80MBYRG
8$8,229,126,188,721,179,000$6,745,584,434,983,253,000.00$20,930$2,228.20+$8229126188721.16MBYRG
9$27,513,861,758,065,720,000$18,708,696,736,134,060,000.00$24,792$3,191.91+$27513861758065.70MBYRG
10$58,669,749,657,316,940,000$29,229,917,576,186,618,000.00$30,274$4,689.40+$58669749657316.91MBYRG

BYRG vs JNJ: Complete Analysis 2026

BYRGStock

Buyer Group International, Inc. operates as an exploration and development stage precious metals mining company. It primarily explores for gold, silver, platinum, rhodium, iron, and other minerals in North America and Greenland. The company holds a joint venture interest in a property consisting of 22 mineral lode BLM claims covering approximately 440 hectares located in the French Creek region of the Medicine Bow Mountains in Carbon County, Wyoming. It also acquires and develops interests in real estate; and produces feature films. The company was formerly known as Curlew Resource Corporation. Buyer Group International, Inc. was founded in 1994 and is based in Leander, Texas.

Full BYRG Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this BYRG vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BYRG vs SCHDBYRG vs JEPIBYRG vs OBYRG vs KOBYRG vs MAINBYRG vs ABBVBYRG vs MRKBYRG vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.